Abiraterone in metastatic prostate cancer without previous chemotherapy.

@article{Ryan2013AbirateroneIM,
  title={Abiraterone in metastatic prostate cancer without previous chemotherapy.},
  author={C. Ryan and M. Smith and J. D. de Bono and A. Molina and C. Logothetis and P. de Souza and K. Fizazi and P. Mainwaring and J. M. Piulats and S. Ng and J. Carles and P. Mulders and Ethan Basch and E. Small and F. Saad and D. Schrijvers and H. Van Poppel and S. Mukherjee and H. Suttmann and W. Gerritsen and T. Flaig and D. George and E. Yu and E. Efstathiou and A. Pantuck and E. Winquist and C. Higano and Mary-Ellen Taplin and Y. Park and T. Kheoh and T. Griffin and H. Scher and D. Rathkopf},
  journal={The New England journal of medicine},
  year={2013},
  volume={368 2},
  pages={
          138-48
        }
}
  • C. Ryan, M. Smith, +30 authors D. Rathkopf
  • Published 2013
  • Medicine
  • The New England journal of medicine
  • BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. METHODS In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free… CONTINUE READING
    1,983 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives… Expand
    ConditionsMetastatic Castration-Resistant Prostate Cancer (mCRPC)
    InterventionDrug
    Interventional Clinical Trial
    This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or… Expand
    ConditionsProstate Cancer
    InterventionDrug
    Interventional Clinical Trial
    The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best… Expand
    ConditionsMetastatic Castrate Resistant Prostate Cancer
    InterventionDrug, Radiation
    Interventional Clinical Trial
    Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in… Expand
    ConditionsProstate Cancer
    InterventionDrug
    Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
    • 707
    • PDF
    Enzalutamide in metastatic prostate cancer before chemotherapy.
    • 1,765
    • PDF
    Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer
    • 795
    • PDF
    Abiraterone's efficacy confirmed; time to aim higher.

    References

    SHOWING 1-10 OF 38 REFERENCES
    Abiraterone and increased survival in metastatic prostate cancer.
    • 3,314
    • PDF
    Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
    • C. Ryan, M. Smith, +9 authors E. Small
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2010
    • 353
    Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
    • 132
    Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
    • 4,819
    • PDF
    Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
    • G. Attard, A. Reid, +16 authors J. D. de Bono
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2009
    • 548
    A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
    • 1,366
    Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
    • 4,112
    • PDF